Latest Articles

Lubrizol Launches Innovative Apisolex™ Technology to Improve Solubility & Simplify Manufacturing of Parenteral Drug Products

Posted by LLS Health Technical Team | 05/03/2022

Apisolex™ technology provides formulators with a safe, polyamino-acid-based excipient to enhance the solubility of BCS Class II and IV APIs, including oncology agents, for parenteral delivery.

Categories: Pharmaceuticals, News

Tackling the Trends - How Excipient Technologies Enable Oral Solid Innovation

Posted by LLS Health Technical Team | 04/14/2022

Oral solid dosage forms, such as tablets, represent the largest segment of the pharmaceutical market. Despite the long history of oral solids in pharmaceuticals, there is still high demand for innovation. For new oral drugs to be commercially successful, it is key that they are easy to manufacture, cost-effective, and patient-friendly. Excipient technologies, such as Carbopol® polymers, can enable for formulator- and patient-centric benefits for these products. Learn more in this article. 

Categories: Pharmaceuticals

Excipients for Solubility Enhancement: Enabling Oral and Injectable Formulations

Posted by LLS Health Technical Team | 03/29/2022

Excipient-enabled approaches to solubility enhancement can accelerate drug development by leveraging established, scalable manufacturing techniques. In this post, we discuss common formulation tactics for BCS Class II and IV APIs and introduce Lubrizol’s novel solubility-enhancing excipients, oral-grade Apinovex™ polymer and injectable-grade Apisolex™ polymer.  

Categories: Pharmaceuticals
Commercial Timeline

Can Your Medical Device Design Partner Help You Meet Your Commercialization Timeline?

Posted by LLS Health Technical Team | 02/01/2022

Whether your focus is in electrophysiology, neurovascular, structural heart, vascular peripheral intervention or specialized/localized drug delivery, working with a skilled design and development team helps you achieve desired design requirements on schedule and in budget.  

Categories: Medical Devices
NAC regulatory

Not All Carbomers are Created Equal: Understanding Regulatory Best Practices When Sourcing Carbomer Excipients

Posted by LLS Health Technical Team | 01/31/2022

In this post Lubrizol Life Science Health explores the regulatory requirements governing excipient safety for the United States as an example of best practice to help formulators understand how to select the most appropriate carbomer for their needs.

Categories: Pharmaceuticals, Regulatory
LLS Health Corona Expansion

Announcement: Expansion of North American Medical Device Design Center Supports Integrated Approach

Posted by LLS Health Technical Team | 01/11/2022

Lubrizol Life Science Health is committed to providing a single-source solution that supports customers from concept to commercialization for their medical device solutions. The recent expansion of our U.S. Medical Device Design Center represents the next phase of this commitment.

Categories: Medical Devices, News
Integrated Approach

The Advantages of an Integrated Approach to Medtech Development

Posted by LLS Health Technical Team | 11/10/2021

OEMs and startups alike increasingly see the advantages of working with an integrated medical device development provider that can support projects from concept to commercialization.

Categories: Medical Devices
Patient-Centric Drug Development

Addressing the Challenges of Patient-Centric Drug Development

Posted by LLS Health Technical Team | 10/26/2021

The need to consistently place the patient at the center of development and manufacturing decisions has been key in the pharma industry. Lubrizol Life Science Health explores the meaning of patient centricity and key considerations that pharmaceutical companies should bear in mind to ensure successful development of a truly patient-centric drug product.

Categories: Pharmaceuticals
EUMDR

Device Makers Face New Challenges Under EU MDR

Posted by LLS Health Technical Team | 10/25/2021

The EU Medical Device Regulation 2017/745 (MDR) that went into effect May 26, 2021, presents a number of challenges for medical device manufacturers, especially makers of implantable and invasive devices.

Categories: Medical Devices, Regulatory
Biocompatibility

More than Materials: A Risk-Based Framework for Biocompatibility Assessment

Posted by LLS Health Technical Team | 10/13/2021

The safety of a medical device is of utmost concern and importance at all times during its development, manufacturing, regulatory submission and use. One critical step in establishing the safety of a device is to evaluate how the device interacts with the body. Device makers’ materials suppliers may be helpful in conducting the evaluations at both the material and device levels.

Categories: Medical Devices, Regulatory
Mucoadhesion formulation

Guide: Initial Formulation Considerations for Mucoadhesive Drug Products

Posted by LLS Health Technical Team | 10/07/2021

In this blog, we discuss key initial formulation considerations when designing mucoadhesive dosage forms, such as those involving the drug, inactive ingredients, and intended site of action.

Categories: Pharmaceuticals
Oral Care - Mucoadhesion

A Guide to Meeting Consumer’s Needs in Oral Care: Long-Lasting Properties

Posted by LLS Health Technical Team | 08/24/2021

Every market has unique demands when it comes to the properties of oral care products. However, no matter the market, the ability to promote longer-lasting properties of oral care products will give a brand greater appeal in an increasingly saturated marketplace. 

Categories: Pharmaceuticals
Not All Carbomers are Equal

Not All Carbomers are Created Equal: Why Quality Needs to Come First When Selecting Excipients

Posted by LLS Health Technical Team | 08/19/2021

To penetrate the markets, manufacturers must ensure that drug products comply with the local regulations. In an industry where the global regulatory environment is fragmented, developers and manufacturers need to know the standard of their carbomers. 

Categories: Pharmaceuticals
Apinovax - grid

Harnessing Excipients to Solve the Bioavailability Challenge

Posted by LLS Health Technical Team | 08/05/2021

As much as 40-70% of new APIs are poorly water soluble, having negative implication for their effectiveness. To address this issue and ensure the successful commercialization of these products, solubility enhancement is essential. In our latest blog, we explore solubility enhancement techniques.

 

Categories: Pharmaceuticals
Mucoadhesion

4 Ways Mucoadhesion Can Benefit Drug Products

Posted by LLS Health Technical Team | 07/21/2021

A key factor in the success and effectiveness of many drug products is whether or not they are “mucoadhesive”. In this blog, we will explore four key ways mucoadhesion, when optimized, can improve over-the-counter (OTC) or prescription (Rx) drug products. 

Categories: Pharmaceuticals
Patient Centric - L

Differentiating Your Oral Drug Product - Consider Consumer Challenges

Posted by LLS Health Technical Team | 01/28/2021

While advancements in drug delivery are continually improving drug efficacy and bioavailability, there are still significant areas of unmet need in the market. This post discusses some key challenges of oral drug formulations and why they are important to address for patient health and differentiation in a crowded market. We uncover strategies for overcoming these challenges, including extended drug release, taste masking, and tablet size reduction.

Categories: Pharmaceuticals
Topical drug delivery

How Sensory Properties are Driving Topical Drug Product Development

Posted by LLS Health Technical Team | 12/08/2020

In this post, Lubrizol Life Science Health (LLS Health) discusses the importance and benefits of topical drug delivery, as well as how these sensory properties are influencing topical development and differentiation. LLS Health then reviews the significance of the FDA's Inactive Ingredient Database (IID) and the components needed to create a topical drug with patient-centric attributes.

Categories: Pharmaceuticals
Rx-to-OTC

Rx-to-OTC Switches: Growth, Drivers & The Role of Patients

Posted by LLS Health Technical Team | 11/09/2020

More than 700 products have made the switch from Rx to OTC over the past several decades, but recent years have seen an upswing. In this blog post, LLS Health discusses growth drivers in Rx-to-OTC switches, the benefits of converting a product to OTC, and how patient considerations are shaping product development. 

Categories: Pharmaceuticals

About the Blog

Welcome to the Blog. Our mission is to accelerate your success through partnership and proactive innovation. This blog will provide unique perspectives from the best in the business. We are dedicated to sharing our extensive market knowledge and formulation expertise to help our partners improve patient outcomes.

Categories

Follow Us

Follow us on LinkedIn

Updates on new blog posts, capabilities, industry expertise and more from Lubrizol Life Science, Health.

Subscribe for Updates

Subscribe

Get immediate access to new blog posts in your inbox.